Post Profile

Actelion to investigate all-oral MS combination therapy

ZURICH (Reuters) - Swiss biotech group Actelion Ltd will investigate an all-oral combination therapy for patients with relapsing multiple sclerosis (RMS), it said, calling it the first study of this approach for treating the neurological disorder.
read more


Related Posts

Relapses Reduced In Multiple Sclerosis Patients By New Oral Drug

Health : Medical News Today

A new oral drug has been shown in a large international clinical trial to significantly reduce the relapse rate of people with multiple sclerosis and to slow the progression of the disease. The results of the Phase 3 trial of the dr...

Novartis says MS drug cut risk of disability advance in study

Health : Reuters: Health

ZURICH (Reuters) - Novartis's investigational multiple sclerosis drug cut the risk of disability progression in patients with a tough-to-treat form of the disease versus a placebo, the Swiss company said on Saturday, citing a new an...

An Oral Disease Modifying Drug For Relapsing Remitting Multiple Sclerosis Would Earn High Patient Shares In Both Europe And The United States

Health : Medical News Today

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an oral disease-modifying therapy for relapsing-remitting multiple sclerosis would earn a 50 percent pat...

Investigational Oral Multiple Sclerosis Therapy Teriflunomide (Aubagio™()) Significantly Reduced Relapse Rate AndDisability Progression

Health : Medical News Today

Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced the publication of the pivotal Phase III TEMSO study with investigational once-daily oral medication teriflunomide in The New England Journal of Medicine (NEJ...

Oral Therapy Teriflunomide (Aubagio™()) Significantly Reduces Relapses Leading To Hospitalization Of Patients With Multiple Sclerosis

Health : Medical News Today

Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced new data from the pivotal TEriflunomide Multiple Sclerosis Oral (TEMSO) Phase III trial showing that once-daily oral teriflunomide significantly reduced annua...


Copyright © 2016 Regator, LLC